Since 2008, DexCom and Insulet have been working together to develop diabetes management systems. DexCom paired its continuous glucose monitoring system with Insulet’s OmniPod insulin device. However, that partnership is coming to an end.
According to an article by Diabetes Mine, Insulet has already ended its working relationship with DexCom. The company also stated that it has a new partnership with an undisclosed partner for the production of an insulin infuser with a CGM.
Based on comments from DexCom, the split may have not been on good terms. Terry Gregg in the CEO of ExCom. In remarks shared with Diabetes Mine, he said, "The official agreement isn't actually terminated.” He continued, "We're just not moving forward at this time and we don't expect to in the future. I believe Insulet is making a mistake, but it is their mistake to make."
According to Insulet, the company dropped the partnership due to concerns over DexCom’s multi-component system. DexCom’s system requires both a connected monitor and the OmniPod device. Insulet, on the other hand, believes that the future of diabetes management is in one-site technology.
Fortunately, DexCom hasn’t been abandoned by all its partners. In 2012, the company signed a contract with Tandem Diabetes Care to develop an insulin pump with a specialized integrated blood sugar monitor. As of now, Medtronic’s Paradigm device is the only integrated system on the market.